Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p-or Refractory to Fludarabine - Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

被引：0

作者：

Stilgenbauer, Stephan

Cymbalista, Florence ^{[2
]}

Leblond, Veronique ^{[3
]}

Delmer, Alain ^{[4
]}

Zenz, Thorsten ^{[1
]}

Winkler, Dirk ^{[1
]}

Buehler, Andreas

Mack, Silja

Busch, Raymonde ^{[5
]}

Ibach, Stefan

Choquet, Sylvain ^{[3
]}

Dartigeas, Caroline

Cazin, Bruno ^{[6
]}

Tournilhac, Olivier ^{[7
]}

Rieger, Michael ^{[8
]}

Soekler, Martin ^{[9
]}

Seiler, Till ^{[10
]}

Schetelig, Johannes ^{[11
]}

Dreger, Peter ^{[12
]}

Hallek, Michael ^{[13
]}

Doehner, Hartmut ^{[14
]}

机构：

[1] Univ Ulm, Dept Internal Med 3, Ulm, Germany

[2] CHU Avicenne, Lab Haematol & Cytognetet, Bobigny, France

[3] Hop La Pitie Salpetriere, Paris, France

[4] Hop Robert Debre, CHU Reims Hematol, Reims, France

[5] Tech Univ Munich, D-8000 Munich, Germany

[6] Ctr Hosp Reg Univ Lille, Serv Malad Sang, Lille, France

[7] CHU Clermont Ferrand, Serv Hematol Adultes & Therapie Cellulaire, Clermont Ferrand, France

[8] Univ Heidelberg, D-6900 Heidelberg, Germany

[9] Univ Tubingen, D-72074 Tubingen, Germany

[10] Univ Munich, D-80539 Munich, Germany

[11] Univ Hosp Carl Gustav Carus, Med Clin 1, Dresden, Germany

[12] Univ Klinikum, Med Klin & Poliklin 5, Heidelberg, Germany

[13] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[14] Univ Ulm Klinikum, Ulm, Germany

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：406 / 406

页数：1

共 13 条

[1] Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in "ultra High-risk" CLL: Final Results from the CLL2O Phase II Study
Stilgenbauer, Stephan
Cymbalista, Florence
Leblond, Veronique
Delmer, Alain
Ibach, Stefan
Choquet, Sylvain
Dartigeas, Caroline
Cazin, Bruno
Tournilhac, Olivier
Pegourie, Brigitte
Seiler, Till M.
Soekler, Martin
Zirlik, Katja
Alt, Juergen
Huber, Henriette
Bloehdorn, Johannes
Tausch, Eugen
Zenz, Thorsten
Hallek, Michael
Schetelig, Johannes
Dreger, Peter
Doehner, Hartmut
BLOOD, 2014, 124 (21)
[2] Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW
Stilgenbauer, Stephan
Cymbalista, Florence
Leblond, Veronique
Delmer, Alain
Winkler, Dirk
Buehler, Andreas
Zenz, Thorsten
Mack, Silja
Busch, Raymonde
Hinke, Axel
Choquet, Sylvain
Dartigeas, Caroline
Cazin, Bruno
Tournilhac, Olivier
Rieger, Michael
Alt, Juergen
Soekler, Martin
Schetelig, Johannes
Dreger, Peter
Hallek, Michael
Doehner, Hartmut
BLOOD, 2011, 118 (21) : 1231 - 1231
[3] Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG)
Stilgenbauer, Stephan
Winkler, Dirk
Buehler, Andreas
Zenz, Thorsten
Groner, Sija
Busch, Raymonde
Hensel, Manfred
Duehrsen, Uhich
Finke, Juergen
Dreger, Peter
Jaeger, Ulrich
Lengfelder, Eva
Truemper, Lorenz
Soeling, Ulrike
Schlag, Rudolf
Hallek, Michael
Doehner, Hartmut
BLOOD, 2007, 110 (11) : 918A - 918A
[4] Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW
Stilgenbauer, Stephan
Cymbalista, Florence
Leblond, Veronique
Delmer, Alain
Mack, Silja
Buehler, Andreas
Winkler, Dirk
Zenz, Thorsten
Busch, Raymonde
Ibach, Stefan
Choquet, Sylvain
Caroline, Dartigeas
Cazin, Bruno
Tournilhac, Olivier
Seiler, Till M.
Zirlik, Katja
Alt, Juergen
Soekler, Martin
Schetelig, Johannes
Dreger, Peter
Hallek, Michael
Doehner, Hartmut
BLOOD, 2012, 120 (21)
[5] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
Stilgenbauer, S
Winkler, D
Kröber, A
Kienle, D
Hallek, M
Hensel, M
Lengfelder, E
Trümper, L
Dreger, P
Jäger, U
Döhner, H
BLOOD, 2004, 104 (11) : 140A - 140A
[6] Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
Stilgenbauer, Stephan
Zenz, Thorsten
Winkler, Dirk
Buehler, Andreas
Groner, Sija
Busch, Raymonde
Hensel, Manfred
Duehrsen, Ulrich
Finke, Juergen
Dreger, Peter
Jaeger, Ulrich
Lengfelder, Eva
Truemper, Lorenz H.
Soeling, Ulrike
Schlag, Rudolf
Hallek, Michael
Doehner, Hartmut
BLOOD, 2008, 112 (11) : 127 - 127
[7] The activity of alemtuzumab is independent of p53 mutational status in fludarabine refractory CLL:: Interim analysis from the CLL2H study of the GCLLSG
Zenz, T.
Haebe, S.
Denzel, T.
Winkler, D.
Kroeber, A.
Kienle, D.
Hallek, M.
Hensel, M.
Lengfelder, E.
Truemper, L.
Dreger, P.
Jaeger, U.
Doehner, H.
Stilgenbauer, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 42 - 42
[8] The activity of alemtuzumab is independent of P53 mutational status in fludarabine refractory CLL:: Final analysis from the CLL2H study of the GCLLSG
Zenz, T.
Haebe, S.
Denzel, T.
Winkler, D.
Hallek, M.
Hensel, M.
Lengfelder, E.
Dreger, P.
Jaeger, U.
Doehner, H.
Stilgenbauer, S.
ANNALS OF ONCOLOGY, 2008, 19 : 193 - 194
[9] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group
Elter, Thomas
James, Rojin
Stilgenbauer, Stephan
Ritgen, Matthias
Hallek, Michael
Engert, Andreas
BLOOD, 2008, 112 (11) : 1087 - 1087
[10] Consolidation therapy with subcutaneous alemtuzumab following induction treatment with oral FC (fludarabine and cyclophosphamide) in previously untreated patients aged 65-70 years with advanced stage chronic lymphocytic leukemia (CLL):: A phase II trial of the FCGCLL/MW.
Delmer, Alain
Lepretre, Stephane
Cazin, Bruno
Feugier, Pierre
Tournilhac, Olivier
Leporrier, Michel
Dreyfus, Brigitte
Mahe, Beatrice
Thieblemont, Catherine
Divine, Marine
Levy, Vincent
Leblond, Veronique
Cymbalista, Florence
Letestu, Remy
BLOOD, 2006, 108 (11) : 801A - 801A

← 1 2 →